0001437749-26-016764
SEC filingQUELIMMUNE customer adoption drove 69% revenue growth and narrower operating losses versus prior year, reflecting cost discipline amid commercialization progress, though ongoing cash burn highlights funding needs for R&D and expansion.
SeaStar Medical Holding Corporation reported Q1 FY2026 results reflecting progress in QUELIMMUNE commercialization amid persistent operational losses and cash usage. Revenue grew 68.9% year-over-year to $495 thousand from $293 thousand, primarily attributable to increased customer adoption of QUELIMMUNE as of March 31, 2026 compared to the prior year. This drove gross profit up 53.2% to $449 thousand, yielding a 90.7% gross margin, as the company's selective cost of goods supported scaling sales without proportional expense increases.
Cash flow from operations used $2.8 million, up slightly from $2.7 million prior year, tied to vendor payment timing amid revenue ramp. Operating margin stood at -727.9%, consistent with loss from operations as a percentage of net sales, underscoring high fixed costs relative to emerging revenue. Management notes that proceeds from potential warrant exercises would support general corporate purposes and liquidity.
Looking ahead, additional funding is critical; without it, the company could delay or suspend R&D for its Selective Cytopheretic Device (SCD) and next-generation versions, or future commercialization, negatively impacting prospects. As operations expand, G&A is expected to rise with hires, travel, ERP systems, and branding. These dynamics position SeaStar to leverage QUELIMMUNE momentum, provided capital supports the path from adoption to sustainable profitability.